We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing ...

Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation.

Biotechnology company Veracyte (NASDAQ:VCYT) is set to replace Triumph Group (NYSE:TGI) in the S&P SmallCap 600 index prior to the market open on Tuesday, July 29. VCYT shares were +6.49% Friday ...

View the latest Veracyte Inc. (VCYT) stock price, news, historical charts, analyst ratings and financial information from WSJ.

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July ...

Veracyte, Inc. (NASDAQ:VCYT) is not on our list of 30 Most Popular Stocks Among Hedge Funds.As per our database, 30 hedge fund portfolios held Veracyte, Inc. (NASDAQ:VCYT) at the end of the fourth ...

Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners ...

Veracyte VCYT is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The company’s Decipher franchise continues to be a strong tailwind, with ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides a look back at a ...

Veracyte, Inc. (NASDAQ:VCYT) generated revenue of $114.5 million in the first quarter of fiscal 2025, marking a 18% increase from last year’s comparable quarter.

Short interest in Veracyte Corp (XNAS:VCYT) decreased during the last reporting period, falling from 280.30M to 275.20M. This put 1.17% of the company's publicly available shares short.